Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Mayo Clin Proc. 2018 Nov;93(11):1664-1677. doi: 10.1016/j.mayocp.2018.04.033.
Hypertension complicates up to 10% of pregnancies worldwide. Pregnancy hypertension is defined as systolic blood pressure (BP) equal to or greater than 140 mm Hg or diastolic BP equal to or greater than 90 mm Hg, usually on the basis of measurements in office/clinic settings and using various BP devices. Hypertensive disorders of pregnancy are classified into (1) chronic hypertension diagnosed before pregnancy or before 20 weeks' gestation, (2) gestational hypertension diagnosed at equal to or greater than 20 weeks, or (3) preeclampsia, defined restrictively as gestational hypertension with proteinuria or broadly as gestational hypertension with proteinuria or an end-organ manifestation consistent with preeclampsia. Absolute BP values equal to or greater than 140/90 mm Hg are associated with increased maternal and perinatal risks, particularly with preeclampsia. This review focuses on antihypertensive therapy of hypertensive disorders of pregnancy as a specific management strategy. Underpinning this therapy is the need for accurate measurement of BP, agreed-upon classification of pregnancy hypertension, agreed-upon BP thresholds for enhanced surveillance and antihypertensive treatment, and collaborative teamwork in management. Challenges relate to the methodology of studies on which care is based, as well as aspects of the care itself, particularly the unregulated use of home BP monitoring. Pitfalls include the unsubstantiated belief that nifedipine and magnesium sulfate cannot be used together and the perception that severe hypertension and nonsevere hypertension are separate entities rather than lying along a spectrum of BP values. The following must be addressed by future research: guidance for nuanced care as women transition between severe and nonsevere hypertension, personalized antihypertensive therapy, and incorporation of women's values into research priorities and clinical practice when antihypertensive care is chosen.
高血压影响全球多达 10%的妊娠。妊娠高血压定义为收缩压(BP)等于或大于 140 mmHg 或舒张压等于或大于 90 mmHg,通常基于办公室/诊所环境中的测量值,并使用各种 BP 设备。妊娠高血压疾病分为(1)妊娠前或妊娠 20 周前诊断的慢性高血压,(2)妊娠 20 周及以后诊断的妊娠期高血压,或(3)定义严格的子痫前期,即妊娠期高血压伴蛋白尿,或广义上的妊娠期高血压伴蛋白尿或与子痫前期一致的终末器官表现。等于或大于 140/90 mmHg 的绝对 BP 值与增加的母婴风险相关,特别是与子痫前期相关。本综述重点关注妊娠高血压疾病的降压治疗作为一种特定的管理策略。这种治疗的基础是需要准确测量 BP、对妊娠高血压的一致分类、对强化监测和降压治疗的一致 BP 阈值,以及管理中的协作团队工作。挑战涉及护理所依据的研究方法以及护理本身的各个方面,特别是家庭 BP 监测的不受监管使用。陷阱包括不合理地认为硝苯地平和硫酸镁不能一起使用,以及认为严重高血压和非严重高血压是两个独立的实体,而不是沿着 BP 值谱的观点。未来的研究必须解决以下问题:为女性在严重和非严重高血压之间过渡提供细致护理的指导、个性化降压治疗,以及在选择降压护理时将女性的价值观纳入研究重点和临床实践。